After Amgen, DISCO lands AbbVie deal worth up to $2.5B

Cologne-based DISCO Pharmaceuticals has signed a cancer drug discovery deal with AbbVie, securing $40 million (€36.5 million) upfront and potentially up to $2.5 billion (€2.3 billion) in additional payments. It is the German biotech's second major pharma partnership this year, following its January agreement with Amgen.

ADVERTISEMENT

Why it matters: DISCO is becoming a repeat Big Pharma partner while its own pipeline remains preclinical. AbbVie’s upfront payment alone roughly matches the €36 million the company raised in seed financing, giving it another route to advance its cancer-cell mapping technology toward medicines.

Zoom in: Under the agreement, DISCO will conduct specified research activities, after which AbbVie can exercise options to obtain exclusive licenses to selected programs for further development. Beyond the upfront payment, DISCO is eligible for up to $2.5 billion in option, development and other milestone payments, plus tiered royalties on worldwide net sales. The companies have not disclosed the number of programs involved or their specific cancer targets.

How it works: DISCO’s proprietary DISCOtech platform maps the surfaceome, the complete set of proteins displayed on a cell’s surface, to identify previously overlooked cancer targets. The company’s approach goes beyond identifying individual proteins and looks for pairs of surface antigens that appear together on cancer cells but are less likely to occur in the same combination on healthy tissue.

The resulting bispecific antibodies use a mechanism called AND-gating: They are engineered to bind strongly only when both antigens are present on the same cell. Many cancer targets are also expressed on healthy cells, limiting the effectiveness and safety of treatments such as antibody-drug conjugates (ADCs) and T-cell engagers. By requiring two targets rather than one, AND-gating could improve tumor selectivity and reduce unwanted toxicity.

DISCO is developing both AND-gated ADCs, which deliver toxic payloads to cancer cells, and T-cell engagers, which recruit immune cells to destroy them. The AbbVie announcement does not specify which therapeutic formats the collaboration will pursue. “Our AND-gated approach is designed to selectively target tumor cells while sparing healthy tissue,” said Mark Manfredi, DISCO’s CEO.

Backstory: In January 2026, DISCO signed an exclusive licensing agreement with Amgen worth up to $618 million, plus royalties. That partnership focused on a cancer-cell surface target discovered through DISCO’s technology, with Amgen securing worldwide development and commercialization rights. The AbbVie deal takes a different approach, focusing on the discovery and development of therapies that recognize combinations of cancer-cell targets.

AbbVie is also no stranger to DISCO. Its investment arm, AbbVie Ventures, participated in the company’s €36 million seed financing, completed in December 2025 alongside investors including Sofinnova Partners, M Ventures and Panakes Partners.

The Cologne biotech, which European Biotechnology selected among its 10 European startups to watch in 2026, is also advancing its own programs toward clinical development. Its lead efforts target small cell lung cancer and microsatellite-stable colorectal cancer.

What to watch: The headline $2.5 billion remains contingent on future options and milestones, and DISCO’s AND-gated approach has yet to demonstrate its promised selectivity in patients. With two major pharma agreements secured, the next challenge is turning the platform’s discoveries into medicines that can deliver results in the clinic.

YOU DON`T WANT TO MISS ANYTHING?

Sign up for our newsletter!